Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
暂无分享，去创建一个
G. Rustin | I. Vergote | L. Dirix | J. Bendell | P. Fracasso | C. Poole | C. Pippitt | L. Duska | N. Reed | J. Micha | C. Gennigens | V. Armenio | D. Spitz | Agustin Garcia | Raoudha Soufi-Mahjoubi | G. Dark | A. Leung | Carol Zhao | E. Ibrahim